The avian infectious bronchitis virus (IBV) multiepitope based peptide EpiC was found to be effective in inducing strong humoral and cellular responses against IBV. In this study, the gene EpiC was introduced into Lactococcus lactis NZ3900, and three recombinant strains expressing EpiC in intracellular and extracellular forms were constructed. SDS-PAGE and Western blot results indicated that EpiC was successfully expressed and had good immunoreactivity with chicken anti-IBV serum. Fusion of the signal pepitide gene SPusp45 and the nine-peptide LEISSTCDA encoding oligonucleotide to EpiC increased the secretion of EpiC, but reduced the total yields of EpiC. Oral immunization to specific-pathogen-free (SPF) chickens with recombinant strains induced significantly higher levels of humoral immune responses, and provided protection against lethal dose challenge by the IBV SAIBk strain. These results indicate that it is feasible to use L. lactis as an antigen delivery vehicle in developing oral vaccines against IBV infection.
IBV belongs to the coronaviridae. Infection with IBV causes respiratory disease, nephritis, or weight loss in chickens, and egg production is reduced or anomalous eggs appear in layer chickens. Vaccine immunization is an effective route to control the spread of IB in the poultry industry, 1, 2) while traditional vaccines used against IB have weakness: live attenuated vaccine comes a risk of reverse mutation to become virulent or recombine with other viruses to form a new virus strain, 3, 4) and inactivated vaccine does not elicit a strong enough immune response against coronavirus and shows severe side effects and long-lasting local responses after inoculation. 5, 6) Multi-epitope based peptide EpiC, containing B-cell linear epitope SP 540{564 , T-cell linear epitope NP 67{83 , and cytotoxic-T-lymphocyte (CTL) epitopes mapped to the carboxyl-terminal 120-residue polypeptide of the N protein of the IBV SAIBk strain, has been found to be effective in eliciting neutralizing antibodies against IBV and activizing lymphocytes, and this provides a high protection rate against lethal dose challenge by the IBV SAIBk strain, 7) but the peptide produced in the E. coli strain must be purified before use. Moreover, peptide vaccines must be administrated with adjuvant by injection, resulting in high production costs and huge amounts of manpower. Therefore, to design a new vaccine economically produced and conveniently administrated is an urgent priority.
Lactic acid bacteria (LAB) are promising candidates for the development of mucosal vaccines, and, differently from the attenuated pathogenic bacteria, they are food-grade, non-invasive, nonpathogenic organisms. [8] [9] [10] Oral or nasal immunization with recombinant LAB expressing viral antigens has been found efficient in eliciting significant immune responses. Mucosal immunization of mice with recombinant LAB strains expressing human papillomavirus type 16 (HPV 16) E7 antigen was found to induce efficiently significant immune responses, and to protect mice from HPV 16 challenge. [10] [11] [12] [13] Mucosal inoculations of mice with recombinant LAB expressing SARS Coronavirus spike protein, HIV Env antigen, or hepatitis B virus surface antigen resulted in high levels of IgG and mucosal IgA, and sera from the immunized mice neutralized virus in vitro. [14] [15] [16] The same results were found in orally immunized mice with LAB expressing dengue 2 virus envelope domain III antigen and porcine epidemic diarrhea viral (PEDV) N protein, and the immune serum was found to be potent in neutralizing dengue 2 virus and PEDV in vitro. 17, 18) Oral administration with the recombinant L. lactis strain expressing the capsid protein of porcine circovirus type 2 induced high levels of cap-specific IgG in the sera of the mice. 19) Orally immunized mice with recombinant L. lactis expressing avian influenza virus (H5N1) HA1 antigen showed significant titers of hemagglutinin (HA)-specific serum IgG and fecal IgA, and cellular immunity was also found in both cell proliferation and gamma interferon (IFN-) enzyme-linked immunospot assays. The mice that received the recombinant L. lactis were completely protected from lethal challenge by the H5N1 y To whom correspondence should be addressed. Tel/Fax: +86-028-85471599; E-mail: wanghongning@163.com Abbreviations: CFU, colony forming units; EID 50 , 50% egg infection dose; ELISA, enzyme-linked immunosorbent assay; HA, hemagglutinin; HI, hemagglutination-inhibition; HPV 16, human papillomavirus type 16; IBV, infectious bronchitis virus; LAB, lactic acid bacteria; PEDV, porcine epidemic diarrhea virus; SPF, specific-pathogen-free virus. 20) All the results above indicate that LAB strains are ideal vectors to deliver heterologous antigens to humans or animals in preventing virosis.
However, all the above genetically modified LAB strains have antibiotic-resistant genes as selective markers, which has the potential risk of shifting the antibiotic-resistant gene to immunized hosts or malignant bacteria. In this study, we used the NZ3900/ pNZ8149 system with the food-grade lacF gene as selective marker, and constructed L. lactis strains expressing IBV multi-epitope EpiC. Various expression vectors were constructed to target the protein to the cytoplasm or the culture medium. The EpiC was successfully secreted into the culture medium by fusion of SPusp45 (usp45 is the main protein of L. lactis secreted into the culture medium) 21) and LEISSTCDA (which has been reported to have the ability to enhance secretion efficiency and the expression levels of heterologous proteins in L. lactis) to the peptide. [22] [23] [24] [25] Orally immunized SPF chickens with nisin induced recombinant L. lactis strains elicited humoral immune responses, and protected the chickens from lethal dose challenge of IBV SAIBk strain.
Materials and Methods
Bacterial strains, plasmids, and culture conditions. The bacterial strains and plasmids used in this study are listed in Table 1 . The nephro-pathogenic IBV SAIBk strain was isolated in Sichuan Province of China. 26) E. coli strains were grown in Luria-Bertani medium with shaking at 37 C. L. lactis strains were grown in M17 medium supplemented with 0.5% glucose (GM17) at 30 C without shaking. 27) Recombinant L. lactis strains were cultivated in M17 medium and were selected on Elliker medium (lactose and Bromocresolpurple were added after sterilization). 28) When necessary, ampicillin (100 mg/mL) was added for E. coli. DNA manipulations. Plasmid DNA extraction from E. coli and L. lactis and all DNA purification procedures were carried out following the instructions in the TIANprep Mini Plasmid Kit and the TIANgel Midi Purification Kit (Tiangen, Beijing, China). All restriction enzymes and T 4 DNA ligase were purchased from Takara (Dalian, China), and were used following the manufacturer's instructions. General cloning procedures were performed according to Sambrook et al. 29) Competent E. coli 5 was prepared and transformed by standard techniques. L. lactis NZ3900 was transformed by electroporation according to Holo and Nes. 30) Construction of recombinant plasmids carrying EpiC. The primers used in the amplification of target DNA fragments are shown in Table 2 . All primer synthesis and the DNA sequencing in this study were performed by BGI (Shenzhen, China). To construct the recombinant vector expressing EpiC in cytoplasmic form, the EpiC gene was amplified from pGET-EpiC with primers 1 and 2, and was introduced into pMD19-T for sequencing. All recombined palsmids named here and below needed for sequencing were introduced into the E. coli 5 strain. Right sequenced EpiC was purified from NcoI/SacIdouble digested pMD-EpiC and then introduced into the same digested pNZ8149, forming pNZEpiC.
To construct recombinant vector expressing EpiC in secreted form, the signal peptide gene of usp45 was amplified from NZ3900 with primers 3 and 4 and introduced into pMD19-T for sequencing. pMDSPusp45 and the EpiC gene, cloned from pGET-EpiC with primers 5 and 2, were digested individually with restriction enzymes NsiI and PstI, forming complementary sticky ends. By ligating digested pMDSPusp45 and gene EpiC with T 4 DNA ligase, SPusp-EpiC was amplified from the ligated mixture with primers 3 and 2 and then introduced into pMD19-T for sequencing. Right sequenced pMDSPusp-EpiC was BspHI/SacI-digested for SPusp-EpiC purification, and then introduce SPusp-EpiC into NcoI/SacI-digested pNZ8149 (NcoI and BspHI are isocaudarners), forming plasmid pNZSPEpiC.
To increase the secretion efficiency of EpiC, the synthetic peptide LEISSTCDA encoding oligonucleotide was fused between SPusp and EpiC. The method was as follows: We annealed primers 6 and 7 (5 0 end complementary with NsiI-digested DNA, 3 0 end complementary with XbaI-digested DNA), then phosphorylated the 5 0 end of the annealed oligonucleotide by T 4 polynucleotide kinase (Takara). The EpiC gene was amplified from pGET-EpiC with primers 8 and 2, and then digested by XbaI. We ligated the NsiI-digested pMD-SPusp45, and phosphorylated LEISSTCDA and the XbaI-digested EpiC in the same reaction system by T 4 DNA ligase. We used the ligated mixture as template to amplify SPusp-LEISS-EpiC with primers 3 and 2, then introduced SPusp-LEISS-EpiC into pMD19-T for sequencing. The right sequenced pMD-SPusp-LEISS-EpiC was BspHI/SacI-digested for SPusp-LEISSEpiC purification, and then we introduced SPusp-LEISS-EpiC into NcoI/SacI-digested pNZ8149, forming plasmid pNZSPLEpiC. Three plasmids in all expressing EpiC were constructed (Fig. 1) .
Construction of recombinant L. lactis strains for EpiC expression. Recombinant plasmids pNZEiC, pNZSPEpiC, and pNZSPLEpiC were transformed into competent NZ3900 by electroporation, 30) forming EpiC-expressing strains NZ3900/pNZEpiC, NZ3900/pNZSPEpiC, and NZ3900/pNZSPLEpiC. The recombinant strains were selected on Elliker medium, 27) and were inoculated into fresh M17 medium, incubated overnight at 30 C, diluted 1/25 in 10 mL fresh medium. When they grew to OD 600 about 0.6, 10 ng/mL nisin A (Sigma-Aldrich Chemie, Zwijndrecht, Netherlands) was added. Growth continued 2 h before protein extraction.
Protein extract preparation and Western blot analysis. L. lactis cells were harvested by centrifugation at 4 C, and cell and supernatant fractions were processed separately following Perez et al. 31) Standard procedures were used for SDS-PAGE and Western blot analysis. The yields of EpiC and preEpiC in the cell fractions were quantified by the method described in reference 32, in which the Bradford method was used to quantify soluble protein extracts, and Genetools software (Syngene, Frederick, MD) to analyze the percentage of EpiC. The immunoreactivity of the EpiC produced in the L. lactis cells was detected by a method using chicken anti-IBV serum (China Institute of Veterinary Drugs Control, Beijing, China) as the first antibody, and HRP-conjugated rabbit anti-chicken antibody (Invitrogen, CA, Carlsbad) as the second antibody. The HRP-conjugates were visualized by diaminobenzidine (Tiangen, Beijing, China).
Chicken immunization and virus challenge. L. lactis strains ZN3900/pNZ8149, NZ3900/pNZEpiC, NZ3900/pNZSPEpiC, and NZ3900/pNZSPLEpiC were cultured as described above. Cell pellets were separated by centrifugation, washed twice, and finally suspended in sterile PBS (5 Â 10 10 CFU/mL). Plate counts were performed for each inoculum to determine the number of colony forming units (CFU). SPF chicken embryos were purchased from Beijing Laboratory Animal Research Center (Beijing, China). The chickens were hatched and housed in HEPA-filtered chicken isolators (Fengshi Laboratory Animal Equipment, Suzhou, China). Five groups of SPF chickens (20 chickens in each group) were individually immunized with 5 Â 10 9 CFU of ZN3900/pNZ8149, NZ3900/pNZEpiC, NZ3900/ pNZSPEpiC, and NZ3900/pNZSPLEpiC at a volume of 100 mL on days 7 to 9 and 17 to 19, with the PBS group as negative control. All the groups were challenged with 100 EID 50 (the 50% egg infection dose) of the IBV SAIBk strain by the nasal-ocular route on day 21 after immunization. EID 50 was measured by the method described by Yang et al. 7) Clinical illness signs were recorded daily. The dead chickens were necropsied to confirm death by IBV infection. All chickens lived 7 d after viral challenge were euthanized and necropsied to observe pathological changes in the organs, and kidney tissues were collected for virus detection by RT-PCR.
Enzyme-linked immunosorbent assay (ELISA) for detection of the IgG antibody. Blood samples were collected from the carotid artery on day 35. Sera were prepared from the blood and were stored at À20 C until they were analyzed. The ELISA method was used to quantify EpiC-specific IgG antibody levels. MaxiSorp 96-well plates were incubated overnight at 4 C with 10 mg/mL purified GST-EpiC antigen (100 mL/well) in coating buffer (0.1 M sodium carbonate, 0.02% sodium azide, pH 9.6). As an ELISA coating antigen, the GST-EpiC protein was produced in E. coli srain BL21/pGET-EpiC, 7) purified by GST-SepharoseÔ Resin (BBI, Shanghai, China), and quantified by the Bradford method. 33) The plates were then blocked with 10% skim milk in PBS for 2 h at 37 C, washed twice with PBS containing 0.02% Tween-20, loaded with 100 mL 1:80 diluted serum samples with standard chicken anti-IBV serum as positive control, and incubated for 2 h at 37 C. HRP-conjugated rabbit anti-chicken IgG (1:5,000 in 3% skim milk in PBS) was added to detect antigen-specific antibodies. A mixture of 0.01% H 2 O 2 and o-phenylenediamine (1 mg/mL) in 0.1 M citric acid and 0.2 M Na 2 HPO 4 per well was added as substrate over 20 min, and then 50 mL 2.5 M sulfuric acid was added as stop solution. Finally, OD450 was measured with an ELISA reader (BIO-RAD 680, Tokyo).
Hemagglutination-inhibition (HI) test. Some antisera of each group attained on day 35 above were incubated for 30 min at 56 C before use. The IBV SAIBk strain antigen were made and HA/HI tests were performed following Alexander et al. 34) Phospholipase C type I (PLC 1 ), used to dispose IBV antigen, was purchased from Sigma (St. Louis, MO). Standard chicken anti-IBV serum was used as positive control. Chicken red blood cells, used in both HA and HI tests, were taken from healthy non-immunized cocks, and were stored at 4 C and used within 48 h after collection. The statistical significance of For details of plasmid construction, see ''Materials and Methods'' and Table 1 . PnisA, nisin-inducible promoter; RBS, ribosomal binding site; SPusp, signal peptide of Usp45; Leiss, sequence encoding the LEISSTCDA synthetic propeptide; EpiC, DNA fragment encoding the mature EpiC protein; T, terminator of constructed plasmids.
antibody IgG levels and HI titers of immunized chickens was determined by Student's t-test, where p < 0:05 was considered to be statistically significant.
Results

Three recombinant L. lactis strains carrying EpiC were constructed
The genes used for cytoplasmic and extracellular expression were successfully amplified and confirmed by sequencing, and finally introduced into pNZ8149, forming plasmids pNZEpiC, pNZSPEpiC, and pNZSPLEpiC. The Usp45 signal peptide gene was correctly inserted by introducing isocaudarner BspHI of NcoI at the 5 0 end, without introducing any unnecessary amino acid before the signal peptide. The synthetic propeptide gene LEISSTCDA was positioned immediately behind the processing site of SPusp45.
EpiC was stably expressed by recombinant L. lactis strains SDS-PAGE (Fig. 2) and Western blot (Fig. 3) were performed to identify the intracellular and supernatant proteins expressed by the recombinant strains, with NZ3900/pNZ8149 as negative control. EpiC and preEpiC, with expected sizes of 25 kDa and 29 kDa, were produced in the cell fractions of NZ3900/pNZEpiC, NZ3900/pNZSPEpiC, and NZ3900/pNZSPLEpiC were directly observed in 12% SDS-PAGE gel. In the extracted supernatant protein fractions, EpiC was observed in the NZ3900/pNZSPLEpiC cultures by SDS-PAGE, but only a slight amount of EpiC was detected in supernatant fractions of NZ3900/pNZSPEpiC. Western blot analysis identified EpiC or preEpiC produced by three recombinant strains has good immunoreactivity with IBV immunized serum, and EpiC was successfully secreted into the supernatant with the an expected size of 25 kDa by NZ3900/pNZSPEpiC and by NZ3900/ pNZSPLEpiC. Of all the recombinant strains, intracellular expression strain NZ3900/pNZEpiC gave the highest yield, of about 42 mg/L, after 2 h induction, up to about 18% of the soluble intracellular proteins. Only a trace of EpiC was secreted into the supernatant by fusion of SPusp45 to EpiC, but the total amounts of EpiC and preEpiC produced by NZ3900/pNZSPEpiC (8 mg/L) were greatly decreased compared to NZ3900/pNZEpiC. Fusion of LEISSTCDA between SPusp45 and EpiC increased the secretion efficiency of EpiC, and gave a higher yield of total EpiC (13.8 mg/L) than NZ3900/ pNZSPEpiC, but still lower than NZ3900/pNZEpiC. These results are quite different from what those reported before, that protein secretion increased overall heterologous protein production. [22] [23] [24] [25] Immune responses induced by oral immunization with recombinant L. lactis strains ELISA results indicated that chickens orally administered L. lactis NZ3900/pNZEpiC and NZ3900/ pNZSPLEpiC showed significant antigen-specific humoral antibody IgG responses as compared to the control groups (p < 0:01) (Fig. 4) . The EpiC-specific IgG levels on day 35 from the NZ3900/pNZEpiC and Strains. 1, Protein marker; 2, cytoplasmic proteins of nisin induced NZ3900/pNZ8149; 3, cytoplasmic proteins of nisin induced NZ3900/pNZEpiC; 4, cytoplasmic proteins of nisin induced NZ3900/pNZSPEpiC; 5, cytoplasmic proteins of nisin induced NZ3900/pNZSPLEpiC; 6, supernatant proteins of nisin induced NZ3900/pNZEpiC; 7, supernatant proteins of nisin induced NZ3900/pNZSPEpiC; 8, supernatant proteins of nisin induced NZ3900/pNZSPLEpiC. Arrows indicate locations of expressed proteins. Fig. 3 . Western-Blot of EpiC Expressed by Recombinant L. lactis Strains. 1, Protein marker; 2, cytoplasmic proteins of nisin induced NZ3900/pNZ8149; 3, cytoplasmic proteins of nisin induced NZ3900/pNZEpiC; 4, supernatant proteins of nisin induced NZ3900/pNZEpiC; 5, cytoplasmic proteins of nisin induced NZ3900/pNZSPEpiC; 6, supernatant proteins of nisin induced NZ3900/pNZEpiC; 7, cytoplasmic proteins of nisin induced NZ3900/pNZSPLEpiC; 8, supernatant proteins of nisin induced NZ3900/pNZSPLEpiC. Sera from groups of chickens on day old 35 were collected for EpiC-specific IgG tests. Statistically significant differences (p < 0:02) were detected between the recombinant L. lactis groups and the two control groups. The NZ3900/pNZEpiC and NZ3900/ pNZSPLEpiC groups showed almost the same IgG levels (p > 0:05), and both were higher than NZ3900/pNZSPEpiC (p < 0:02).
Ã Mean ELISA antibody titers significantly different from the control groups (p < 0:05);
ÃÃ Mean ELISA antibody titers very different from control groups (p < 0:01). NZ3900/pNZSPLEpiC groups were higher than the level of the positive control (p < 0:05). Antisera for each group, obtained on day 35, were taken for HI titres. The results indicated that chickens immunized with L. lactis NZ3900/pNZEpiC and NZ3900/pNZSPLEpiC showed significantly higher HI titers than PBS and the NZ3900/pNZ8149 immunized groups (p < 0:01) (Fig. 5) . NZ3900/pNZEpiC induced almost the same level of IgG and HI titers as NZ3900/pNZSPLEpiC (p > 0:05), which are significantly higher than NZ3900/ pNZSPEpiC (p < 0:05). This indicates that both the expression level and the secretion efficiency of the heterologous protein expressed in L. lactis contributed to the immune responses.
Protection against IBV challenge
To evaluate the protective efficacy of the recombinant L. lactis strains, all groups of chickens were challenged with 100 EID 50 of the IBV SAIBk strain. Mortality, clinical illness, numbers of affected chickens detected by RT-PCR, and the protection rate are summarized in Table 3 . Chickens orally immunized with L. lactis NZ3900/pNZEpiC or NZ3900/pNZSPLEpiC shared an 80% protection rate. In contrast, most chickens of the control groups (immunized with NZ3900/pNZ8149 and PBS) had clinical illness signs or were dead, and some chickens without clinical illness signs still had the virus in the kidneys as judged by RT-PCR. These results indicate that L. lactis expressing high yields of multiepitope peptide EpiC might be a good vaccine against virulent IBV challenge.
Discussion
LAB strains have been researched to deliver foreign antigens to mucosal tissues for many years. For their capacity prevention of spread of various of infectious viral diseases have been studied, and the results of animal experiments have indicated that strong corresponding humoral and cellular responses were induced after immunization with recombinant strains, and immunized mice were protected from viral challenge. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] These encouraging results indicated to us that LAB strains might be feasible as mucosal tools to deliver heterologous antigens in animal immunization. Here, we recombined the gene EpiC into the highly efficient expression system NZ3900/pNZ8149, 35, 36) and attained recombinant L. lactis strains expressing EpiC in cytoplamic and secreted forms. This is the first time that SPusp45 and LEISSTCDA have been fused to a heterologous gene in the NZ3900/pNZ8149 system and secreted peptide in the supernatant of culture medium. To use L. lactis as a protein delivery vehicle in the digestive tract of humans or animals, secretion is also preferable because it facilitates interaction between the protein (e.g., enzyme or antigen) and its target (substrate or immune system).
25) The constructed strains should make it possible to determine whether recombinant L. lactis can be used as an EpiC delivery vehicle to elicit immune responses against IBV, and what antigen location induces the most efficient immune responses.
Based on the SDS-PAGE and Western blot results, we found that the intracellular expression bacterium NZ3900/pNZEpiC give the highest yield of EpiC. This indicates that fusion of SPusp45 is not helpful for all the proteins expressed in the LAB strains. The highest levels of EpiC-specific antibody IgG and HI titers were elicited and the highest protection rate was provided by NZ3900/pNZEpiC and NZ3900/pNZSPLEpiC. The results might mean that higher yield of heterologous antigen in the cytoplasmic form of L. lactis can offset the deficiency in secretion, because there is a strong correlation between the immune responses and expressivity of foreign antigens. 37) SPusp45 is not necessary to increase all the proteins expressed in L. lactis, but increased secretion is favorable for immunization, for the far lower levels expressed NZ3900/pNZSPLEpiC provided slightly higher immune responses than NZ3900/pNZEpiC (p > 0:05). In contrast to the PBS groups, chicken immunized with NZ3900/pNZ8149 showed a higher protection rate, probably because mucosal administration of L. lactis increased innate and specific immune responses in the respiratory tract and reduced the tissue damage caused by pathogen infection. 38) Our results identify three recombinant L. lactis strains expressing IBV multi-epitope based peptide EpiC. They indicate that L. lactis produces a recombinant EpiC protein that possesses antigenic properties. Fusion of the signal peptide SPusp45 and the synthetic peptide LEISSTCDA increased the secretion of heterologous Groups. Sera collected on day 35 were tested for HI titers. NZ3900/ pNZEpiC, NZ3900/pNZSPEpiC, and NZ3900/pNZSPLEipC groups showed significantly higher HI titres than the PBS and NZ3900/pNZ8149 groups (p < 0:02). The NZ3900/pNZEpiC and NZ3900/pNZSPLEpiC groups showed almost the same level of HI titers (p > 0:05).
Ã Mean HI titres significantly different from the control groups (p < 0:05); ÃÃ Mean HI titres very different from the control groups (p < 0:01). protein, while might reduce production of total antigens at the same time. Oral administration of L. lactis NZ9000/pNZEpiC and NZ3900/pNZSPLEpiC significantly induced humoral immune responses against IBV in the chickens, protecting them against IBV challenge. These results suggest that recombinant L. lactis is promising in the development of mucosal live vaccines against IBV infection.
